$LLY

Novo Nordisk partners with OpenAI to accelerate drug discovery via AI. Long-term benefits possible, but near-term headwinds from competition and clinical setbacks persist.

Eli Lilly's oncology and immunology portfolios rival its blockbuster weight-loss drugs, positioning the company better than Novo Nordisk for long-term growth.

S&P 500 hits record highs with 84% earnings beats and 15.1% growth, as Magnificent Seven tech giants report this week and Fed meets on rates.

SpaceX's $1.75 trillion IPO valuation exceeds traditional metrics but may be justified by transformational growth potential across Starlink, Starship, and emerging space-based services.

Wall Street projects 170% upside for Viking Therapeutics' obesity drug candidate VK2735, citing superior weight loss and tolerability versus Novo Nordisk and Eli Lilly rivals.

Eli Lilly shows 43% revenue growth and 51% EPS growth, backed by weight-loss drug leadership and $7B cancer acquisition. Forward P/E of 40 remains below historical average.

Amazon launches GLP-1 weight management program through One Medical, leveraging its healthcare ecosystem and logistics capabilities to tap into a market projected to reach nearly $100 billion by 2030.

Eli Lilly's new weight-loss drug Foundayo recorded just 3,707 prescriptions in week two, trailing Novo Nordisk's Wegovy by over 400%, triggering a 4% stock decline.

QXO to acquire TopBuild for $17B. Multiple companies face activist pressure for strategic reviews. Tech and pharma close major deals.

Global radiopharmaceuticals market projected to grow from $8.28B (2026) to $15.21B (2035) amid rising cancer and cardiovascular disease incidence.

Omics clinical trials market grows 8.8% annually from $31.71B in 2025 to $47.78B by 2030, driven by personalized medicine demand and AI advances.

Hims & Hers exploits GLP-1 and estrogen patch shortages, securing steady inventory to position itself as critical pharmaceutical supply anchor amid three-year supply constraints.

Kailera Therapeutics surged 63% on Nasdaq debut as weight-loss drug spinoff from Hengrui Pharma, raising $625M and validating the 'NewCo' model for Chinese pharmaceutical companies.

Novo Nordisk's 72% crash from peaks sparks debate: value trap or buying opportunity amid GLP-1 market competition from Eli Lilly.

DexCom benefits from GLP-1 weight-loss drug adoption regardless of pharmaceutical winner, leveraging competitive moats in CGM technology and ecosystem integration.

Eli Lilly, Vertex Pharmaceuticals, and Intuitive Surgical possess durable competitive moats—patent protection and market dominance—supporting sustained earnings growth through the 2030s.

Inhibrx is fielding takeover interest from major pharma for cancer drug INBRX-106 in potential $9B spin-off; stock surges 39.86%.

Eli Lilly stock fell 2.5% after announcing a $7 billion acquisition of Kelonia Therapeutics for CAR-T cancer therapy, despite positive analyst rating.

Pfizer's experimental monthly GLP-1 injection threatens to disrupt the weight-loss market dominated by Novo Nordisk and Eli Lilly, potentially triggering price competition.

Legend Biotech surges 18% on bullish analyst upgrades and momentum from Eli Lilly's $7B CAR-T acquisition, with CD19/CD20 therapy driving investor enthusiasm.